Stereotactic Ablative Body Radiation

RADIATION3 trials

Sponsors

University of Texas Southwestern Medical Center, Sunnybrook Health Sciences Centre

Conditions

ALK-positive Non-small Cell Lung CancerCancer of ProstateMetastatic Castrate-resistant Prostate CancerProstate AdenocarcinomaProstate CancermCRPC

Phase 2

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

CompletedNCT01818986

University of Texas Southwestern Medical CentermCRPC, Metastatic Castrate-resistant Prostate Cancer

Start: 2013-07-10End: 2021-05-25Updated: 2022-05-06

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

TerminatedNCT02513667

University of Texas Southwestern Medical CenterALK-positive Non-small Cell Lung Cancer

Start: 2015-11-30End: 2021-05-29Updated: 2023-02-03

Unknown Phase

Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer

RecruitingNCT05600400

Sunnybrook Health Sciences CentreCancer of Prostate, Prostate Adenocarcinoma, Prostate Cancer

Start: 2024-03-01End: 2029-06-30Target: 144Updated: 2025-09-09

Related Papers

Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.

Journal of Clinical Oncology2020-05-202 citations